Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced that its Compensation Committee granted non-qualified stock options to purchase an aggregate of 14,100 shares as inducement awards to newly hired employees on Dec 9, 2025. The awards were granted under the company’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price equal to the closing price of Aligos common stock on the grant date and vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly, subject to continued employment.

News Market Reaction

+15.51% 2.1x vol

19 alerts

+15.51% News Effect

+12.6% Peak in 5 hr 28 min

+$11M Valuation Impact

$84M Market Cap

2.1x Rel. Volume

On the day this news was published, ALGS gained 15.51%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.6% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $84M at that time. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 14,100 shares Vesting period: 4 years Initial cliff vesting: 25%

3 metrics

Inducement options 14,100 shares Non-qualified stock options granted to new hires on Dec 9, 2025

Vesting period 4 years Inducement options vesting schedule

Initial cliff vesting 25% Vests on first anniversary of Grant Date

Market Reality Check

Price: $8.07 Vol: Volume 49,645 is at 0.66x...

low vol

$8.07 Last Close

Volume Volume 49,645 is at 0.66x the 20-day average of 75,536 shares. low

Technical Trading at $11.51, above the 200-day MA of $8.47 and mid-range of its 52-week $3.76–$46.80 band.

Peers on Argus

Peers show mixed moves: BYSI up 8.46% while IGMS and ACET are down modestly. Onl...

1 Up

Peers show mixed moves: BYSI up 8.46% while IGMS and ACET are down modestly. Only BYSI appears in the momentum scanner, suggesting ALGS trading reflects company-specific factors rather than a broad biotech move.

Common Catalyst BYSI has same-day clinical trial news, but no shared catalyst with ALGS’s employee inducement grants.

Historical Context

5 past events · Latest: Nov 14 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 14	Inducement grants	Neutral	+9.7%	Equity inducement options granted to new hires under 2024 plan.
Nov 10	Clinical data update	Positive	-2.6%	Positive HBV suppression data for ALG-000184 at The Liver Meeting.
Nov 06	Earnings and pipeline	Negative	-3.1%	Q3 loss, funding runway into Q3 2026, ongoing trial funding needs.
Nov 04	Conference appearances	Neutral	-4.3%	Planned investor conference presentations and webcast availability.
Oct 30	Earnings date notice	Neutral	-4.8%	Announcement of upcoming Q3 2025 financial results release date.

Pattern Detected

News often sees mixed or negative price reactions, with positive clinical data previously met by a modest selloff.

Recent Company History

Over recent months, Aligos has balanced routine news with key clinical and financial updates. A prior inducement grant announcement on Nov 14, 2025 coincided with a 9.72% gain. Positive HBV data at The Liver Meeting on Nov 10, 2025 saw a -2.62% reaction, while Q3 2025 results on Nov 6, 2025 led to a -3.14% move. Conference participation and an earnings date notice in late October–November also saw modest declines. Today’s inducement grants fit this pattern of regular corporate updates.

Market Pulse Summary

The stock surged +15.5% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +15.5% in the session following this news. A strong positive reaction aligns with the company’s prior experience, where a similar inducement grant announcement on Nov 14, 2025 coincided with a 9.72% gain. However, these awards represent routine hiring-related equity rather than a change in fundamentals. Past news flow shows both gains and selloffs around updates, so enthusiasm could fade if investors refocus on clinical milestones and the company’s loss profile.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"pursuant to Aligos’ 2024 Inducement Plan ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 14,100 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 14,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on December 9, 2025 (the “Grant Date”), in connection with the commencement of employment.

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.

The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics

Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

FAQ

What did Aligos (ALGS) announce on December 12, 2025 about employee stock awards?

Aligos announced inducement grants of options for an aggregate of 14,100 shares granted on Dec 9, 2025 under its 2024 Inducement Plan.

How do the Aligos (ALGS) inducement options vest and when do they start vesting?

The options vest over four years: 25% on the first anniversary of the Dec 9, 2025 grant date, then monthly thereafter, subject to continued employment.

What is the exercise price for Aligos (ALGS) inducement grants given Dec 9, 2025?

The exercise price equals the closing price of Aligos common stock on the grant date, Dec 9, 2025.

Why were the Aligos (ALGS) awards granted under the 2024 Inducement Plan?

The awards were granted as inducements material to new hires and issued exclusively under the 2024 Inducement Plan in compliance with Nasdaq Rule 5635(c)(4).

Do Aligos (ALGS) inducement grants affect existing equity plans or employees?

The grants were made specifically to individuals not previously employed by Aligos and are issued under the separate 2024 Inducement Plan.

When were Aligos (ALGS) inducement grants effective and who approved them?

The grants were approved by the Compensation Committee and granted on Dec 9, 2025 in connection with the commencement of employment.